JB
James Basta
EVP, General Counsel

James Basta insider trades: Intellia Therapeutics (NTLA) stock sales

EVP, General Counsel, Intellia Therapeutics Last trade Mar 2, 2026 13 Form 4 filings
$112K
Sold, last 12 months
2 sales
$0
Bought, last 12 months
0 buys
8
Open-market trades
since 2023
2
Companies
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where James reports to the SEC

Open-market buys and sales

8 trades reported on SEC Form 4, newest first

DateStockTypeValue
Mar 2, 2026NTLA↓ Sell$17K
Jan 5, 2026NTLA↓ Sell$96K
Mar 4, 2025NTLA↓ Sell$23K
Jan 3, 2025NTLA↓ Sell$86K
Mar 4, 2024NTLA↓ Sell$76K
Jan 3, 2024NTLA↓ Sell$112K
Mar 2, 2023NTLA↓ Sell$48K
Jan 4, 2023NTLA↓ Sell$42K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other NTLA insiders

Open-market trades in the last 12 months

About James Basta's insider trades

James Basta is EVP, General Counsel at Intellia Therapeutics (NTLA). Since Jan 4, 2023, James has reported no open-market purchases and 8 sales worth $500K on SEC Form 4. In the last 12 months: 2 sales ($112K).

Their filings also include grants and awards (9 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every NTLA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.